جست‌وجوی استاد و پژوهشگر

SADIK VAROLGÜNEŞمشاهده پروفایل

مدرس

• Earthquake Engineering
• Structural Engineering
• Geotechnical Engineering
• +۵ مورد دیگر

Dr. Sadik Varolguneş serves as a Dr. Lecturer in the Faculty of Engineering and Architecture at Bingol University since 2024, following 14 years as a Research Assistant at the same institution. His academic foundation includes a Civil Engineering PhD from Dicle University (2023), Master's degree (2013), and Bachelor's degree from Erciyes University (2001), with professional experience spanning construction management and municipal engineering prior to academia. His educational journey features: Bachelor's Degree in Civil Engineering, Erciyes University (2001) Master's Degree in Civil Engineering, Dicle University (2013) PhD in Civil Engineering, Dicle University (2023) Varolguneş's research bridges earthquake engineering and sustainable construction, with dual focus on seismic resilience and eco-friendly materials. He conducts field investigations of earthquake-damaged structures while developing computational models for performance evaluation. His sustainable construction work applies Analytical Hierarchy Process to green building standards and investigates geopolymers using industrial byproducts like ferrochrome slag. Recent publications demonstrate urgent responses to Turkey's seismic events, particularly the 2023 Kahramanmaraş earthquakes. His 12 journal articles published between 2016-2025 show accelerating output after his PhD, with 7 papers in the last three years. International journals dominate his work (8 articles), primarily addressing earthquake engineering (Natural Hazards, Journal of Earthquake and Tsunami) and sustainable construction (Quality & Quantity). The 2023 Kahramanmaraş earthquakes catalyzed his most productive period, yielding three major studies on seismic performance evaluation, bibliometric analysis, and fault rupture characteristics. Dr. Varolguneş actively leads two nationally funded research projects: as principal investigator for seismic software comparison research and as collaborator on geopolymer development from industrial waste. He teaches core undergraduate courses including Reinforced Concrete High Structures and Construction Management, integrating his pre-academic industry experience with current earthquake engineering research to prepare students for practical challenges in Turkey's seismic landscape.

• HIV-1 persistence
• HIV-1-induced immune dysfunction
• Single-cell genomics
• +۷ مورد دیگر

Ya-Chi Ho is an Associate Professor with Tenure in Microbial Pathogenesis and an Associate Professor on Term in Infectious Diseases at Yale School of Medicine. She serves as Director of Graduate Studies for the Microbiology PhD Program of Biological and Biomedical Sciences. Dr. Ho is affiliated with multiple Yale research centers including the Cancer Immunology program, Center for RNA Science and Medicine, Immunology, Internal Medicine, Microbiology, Virology Laboratories, Yale Cancer Center, and the Yale Center for Systems and Engineering Immunology (CSEI). Dr. Ho's research focuses on understanding HIV-1 persistence and HIV-1-induced immune dysfunction using single-genome and single-cell approaches on clinical samples. Her work has revealed that HIV-1 preferentially persists in cytotoxic CD4+ T cells and identified antigen stimulation and tumor necrosis factor (TNF) as key drivers for the clonal expansion of HIV-1-infected cells. She developed innovative methods including HIV-1 full-length single-genome sequencing (Cell 2013) and single-cell HIV-1 SortSeq (Science Translational Medicine 2020), which became standard measurements for studying the HIV-1 latent reservoir. Analysis of Dr. Ho's recent publications shows a strong trend toward single-cell multi-omics approaches to understand HIV persistence mechanisms, with increasing focus on tissue-resident memory T cells, spatial transcriptomics of HIV in tissues, and the intersection of HIV with other conditions like opioid use disorder. Her work bridges molecular virology, immunology, and clinical applications with the ultimate goal of developing an HIV cure. Her notable awards include: Andy Kaplan Prize (2018) Gilead Sciences Research Scholar in HIV (2018) Rudolf J. Anderson Fellowship (2018) Lois E. and Franklin H. Top, Jr. Yale Scholar (2017) Distinguished Alumni Award from National Cheng Kung University (2016) Dr. Ho's research is primarily funded by NIH grants, including an R21 awarded one year after her PhD completion and two R01-level grants secured within one year of starting her lab at Yale. She serves as an investigator for major collaborative projects such as the NIH Structural Biology Center CHEETAH, NIH Martin Delaney Collaboratory BEAT HIV and REACH (UM1), and a P01 grant. Her lab employs cutting-edge single-cell technologies to study HIV-infected cells directly from clinical samples, providing unique insights into HIV persistence mechanisms. The Ya-Chi Ho Lab, located in the Boyer Center for Molecular Medicine, focuses on exploiting molecular virology, genetics, bioinformatics, immunology and single-cell technology to understand the mechanisms of HIV persistence and develop a cure for HIV. The lab's translational approach bridges bench discoveries into clinical applications, with rotation projects available from wet-bench virology/immunology experiments to computational analyses.

• Pediatric Hematology
• Pediatric Oncology
• Sickle Cell Disease
• +۵ مورد دیگر

Dr. Farzana Pashankar is a Professor of Pediatrics (Hematology/Oncology) at Yale School of Medicine with multiple leadership roles including Chair of the Faculty Mentoring Program, Fellowship Director of the Pediatric Hematology & Oncology Program, Director of the Solid Tumor Program, and Children's Oncology Group Site PI. She serves as Disease Aligned Research Team Leader for Pediatrics at Smilow Cancer Center and directs the Pediatric Hematology Oncology Fellowship Program. Dr. Pashankar received her MBBS and MD from University of Pune, India, trained in the United Kingdom earning an MRCP, completed residency at the University of Iowa, and fellowship at British Columbia Children's Hospital before joining Yale in 2005. Her research focuses on three main areas: sickle cell disease, rare tumors, and germ cell tumors. In sickle cell disease, she pioneered studies on pulmonary hypertension in children, demonstrated that hydroxyurea can reverse elevated pulmonary artery pressures, and developed quality improvement projects to reduce emergency department visits and hospitalizations. For rare tumors, she chaired the Infrequent Tumor Subcommittee at COG until 2020, developing guidelines for several rare tumors and completing international clinical trials for adrenocortical carcinoma and nasopharyngeal carcinoma. In germ cell tumors, her research has redefined management of immature teratomas, showing that grade is the most important risk factor for relapse and successfully advocating for observation alone in many cases that previously received chemotherapy. Her publication record shows strong activity in pediatric hematology-oncology with recent work spanning clinical trials, genomic studies of sickle cell complications, treatment guidelines for germ cell tumors, and quality improvement initiatives. Her research bridges clinical care, translational science, and health services research. 2016-2020: Faculty Honor Roll, Yale Pediatric Residency Program 2018: Semifinalist, Pediatric Quality Award, Children's Hospital Association 2015: Howard A. Pearson Pediatric Faculty Teaching Award 2012: Pediatric Residency Program Director's Award 2009: Pediatric Faculty Scholar Award, Yale University School of Medicine Dr. Pashankar actively mentors trainees through multiple roles including Fellowship Director and Chair of the Faculty Mentoring Program. She serves as Principal Investigator for several clinical trials and as Sub Investigator on additional trials. Her work with the Children's Oncology Group spans over 15 years, where she has chaired international trials in germ cell tumors. She collaborates extensively with colleagues at Yale, through the New York Connecticut Consortium, and the New England Pediatric Sickle Cell consortium. Dr. Pashankar's clinical work centers on providing comprehensive care for children with blood disorders and cancer, with particular expertise in sickle cell disease and solid tumors. She emphasizes building long-lasting relationships with families and states that watching advancements in the field that improve cure rates (now 80-85% for childhood cancer) has been a rewarding journey of her career.

Sarah E S Learyمشاهده پروفایل

استاد

• Pediatric brain tumors
• Precision Medicine
• Clinical trials
• +۶ مورد دیگر

Sarah Leary, MD, MS is an Attending Physician and Medical Director of the Pediatric Brain Tumor Program in the Cancer and Blood Disorders Center at Seattle Children's Hospital. She serves as a Professor of Pediatrics at the University of Washington School of Medicine and is an associate of the Fred Hutch Cancer Research Center. Dr. Leary holds the position of Medical Director of Clinical Research at the Ben Towne Center for Childhood Cancer and Blood Disorders Research and leads the Seattle Children's Tumor Banking and Biology study. She also serves as the Seattle Children's site Principal Investigator for the Children's Oncology Group and CONNECT Clinical trials consortia. Dr. Leary completed her MD at University of Tennessee College of Medicine, followed by a Pediatric Residency at Johns Hopkins Hospital, and a Pediatric Hematology/Oncology Fellowship at St. Jude Children's Research Hospital. She further enhanced her research capabilities by earning an MS in Epidemiology from the University of Washington between 2010 and 2014. Dr. Leary's research focuses on clinical trials and novel therapy development for childhood, adolescent and young adult brain tumors. Her recent work emphasizes precision medicine, big data projects, and international collaborations to generate, collect and share molecular and clinical data to support research. She has particular expertise in translational research with a focus on improving outcomes for pediatric brain tumor patients. Her work spans molecular characterization of brain tumors, development of targeted therapies, and innovative immunotherapeutic approaches. Her recent publications demonstrate a strong focus on innovative treatments for pediatric brain tumors, particularly low-grade gliomas and medulloblastoma. Her work spans targeted therapies like RAF inhibitors (tovorafenib), immunotherapies including CAR T-cell approaches, and novel chemotherapy regimens. Much of her research involves leading or participating in major clinical trials through the Children's Oncology Group and other consortia, with an emphasis on molecularly guided treatments that represent the cutting edge of pediatric neuro-oncology. Dr. Leary serves in multiple leadership roles including clinical Vice-Chair of the Central Nervous System Committee of the Children's Oncology Group, chair of the Data Safety Monitoring Committee of the Pediatric Brain Tumor Consortium, and member of the Brain Malignancy Steering Committee of the National Cancer Institute. She leads international data sharing efforts as the lead of the clinical data operations group of the Children's Brain Tumor Network (CBTN) and Co-Chair of the Executive Committee of the INSPiRE consortium, demonstrating her commitment to collaborative research that accelerates progress in the field. Dr. Leary leads the Seattle Children's Tumor Banking and Biology study and is deeply involved with the Ben Towne Center for Childhood Cancer and Blood Disorders Research. Her clinical interests focus specifically on pediatric brain tumors and precision medicine approaches. She is particularly passionate about providing the best care for patients today while working to find cures for every child in the future, as reflected in her statement: 'It is a privilege to work with children, adolescents and young adults as part of a multidisciplinary team of clinicians and researchers who are so dedicated to providing the best care for our patients today while at the same time working to find a cure for every child in the future.'

Rahul Banerjeeمشاهده پروفایل

استادیار

• Multiple myeloma
• AL amyloidosis
• CAR-T therapy
• +۵ مورد دیگر

Rahul Banerjee, MD, FACP is an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine and an Assistant Professor in the Clinical Research Division at Fred Hutch Cancer Center. He is a board-certified hematologist-oncologist specializing in blood cancers, particularly multiple myeloma, AL amyloidosis, and advanced cellular immunotherapies including CAR-T therapy. Dr. Banerjee completed his medical education at Brown University's Alpert Medical School, followed by residency in Internal Medicine at the Hospital of the University of Pennsylvania where he served as Chief Resident at the Philadelphia VA Medical Center. He completed fellowships in Hematology/Oncology and an advanced fellowship in Bone Marrow Transplantation and Cellular Therapy at the University of California San Francisco. He is board certified in Internal Medicine, Hematology, and Medical Oncology by the American Board of Internal Medicine and is a Fellow of the American College of Physicians. His clinical interests focus on multiple myeloma, amyloidosis, and lymphoplasmacytic lymphoma, with particular expertise in CAR-T therapy. His research interests center on toxicity management, digital health, and improving the patient experience during cancer treatment. He emphasizes 'precision health care delivery' that considers side effects, quality of life, financial and logistical considerations, and other factors that impact patients' lives beyond just the cancer itself. Because myeloma is an incurable cancer that patients may live with for years, Dr. Banerjee is passionate about minimizing the burden myeloma places on patients' lives. His extensive publication record includes over 100 peer-reviewed articles focusing on multiple myeloma, cellular immunotherapies, and patient-centered care. His recent research has explored digital health interventions during stem cell transplantation, financial toxicity in hematologic malignancies, and innovations in CAR-T therapy management. Analysis of his most recent publications reveals a strong focus on improving treatment outcomes while reducing patient burden, with particular attention to digital health solutions and precision delivery of care. Fellow, American College of Physicians Member, International Myeloma Working Group Member, Content Committee, American Society for Transplantation and Cellular Therapy (ASTCT) Member, Plasma Cell Disorders Working Committee, CIBMTR Dr. Banerjee serves as Principal Investigator for several clinical trials including 'Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation' and 'Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy.' His work has been presented at major hematology and oncology conferences including ASH, with recent contributions to research on potential functional cures for multiple myeloma and new endpoints that could accelerate drug approvals. Dr. Banerjee sees patients at Fred Hutch Cancer Center locations in South Lake Union and at UW Medical Center – Montlake and is fluent in English, Hindi, and Bengali.

Evan Morris Zeitlerمشاهده پروفایل

استادیار

• Nephrology
• Kidney Disease
• Obesity and Metabolism
• +۲ مورد دیگر

Evan Morris Zeitler, MD is an Assistant Professor of Medicine in the Division of Nephrology and Hypertension at the University of North Carolina at Chapel Hill School of Medicine. His clinical practice specializes in kidney disease with emphasis on metabolic disorders including diabetes and obesity, focusing on patient-centered care where healthcare providers act as advisors and cheerleaders. His educational background includes: Undergraduate studies at Stanford University Medical degree from University of North Carolina at Chapel Hill Residency in Internal Medicine and Pediatrics at UNC Fellowship in Nephrology at UNC Dr. Zeitler's research investigates how diet and obesity contribute to kidney dysfunction through both clinical studies and experimental models. His work spans molecular mechanisms in zebrafish models to large-scale clinical networks, examining obesity-related glomerulopathy, metabolic responses to overfeeding, and pharmacological interventions for weight management in kidney disease patients. He emphasizes patient perspective in developing care plans and maintains active curiosity about human physiology. Analysis of his 15 most recent publications (2013-2025) reveals a concentrated focus on obesity-kidney disease interactions, with significant contributions to clinical guidelines (including ASN guidance on obesity management), experimental models demonstrating reversible kidney damage from high-calorie diets, and investigations into cardiac outcomes in glomerular disease. His work bridges basic science (zebrafish metabolism studies) and clinical practice (CureGN consortium findings). Scientific Awards: No awards listed in available sources Dr. Zeitler mentors medical students and trainees within the Department of Medicine, emphasizing physiological understanding and patient-centered approaches. While specific grant details aren't provided, his active participation in the Cure Glomerulonephropathy Network indicates substantial research funding. His laboratory utilizes zebrafish to model metabolic kidney disorders, examining overfeeding effects and dietary interventions. He maintains clinical appointments through UNC Health and contributes to multidisciplinary teams within the Division of Nephrology and Hypertension, with research extending to environmental exposures, interstitial nephritis, and hormonal disorders impacting kidney function.

Alfonso Avila-Robinsonمشاهده پروفایل

استاد

• Innovation Management
• Technology Forecasting
• Regenerative Medicine
• +۴ مورد دیگر

Alfonso Avila-Robinson is a Professor at Tecnológico de Monterrey's Business School (Campus Santa Fe), specializing in Innovation and Technology Management. His global research experience spans Fraunhofer Institute, RWTH Aachen, Tokyo Tech, and Kyoto University, with expertise in emerging technologies like regenerative medicine and data science. His research focuses on technology intelligence, innovation forecasting, and interdisciplinary R&D , particularly in life sciences. He examines how convergent discoveries translate into disease-curing ventures, leveraging practical experience in Japan's regenerative medicine ecosystem. His work bridges management theory with cutting-edge biotechnologies like stem cells and cancer immunotherapies. His recent publications reveal strong trends in medical device innovation systems (2024), stem cell applications (2022), and quantitative analysis of innovation knowledge bases (2021-2022), consistently published in top journals like Technovation and Scientometrics . Awards & Recognition: MEXT Doctoral Scholarship (Japan, 2008) CONACYT Master's Scholarship (Mexico, 2002) UDEM Academic Scholarship (1995) Mexican Researcher Certification Level 1 As a dedicated educator, he teaches Doctoral Research courses and Innovation in Business Models. His advisory work focuses on doctoral candidates in technology management, while his grants likely support his international research collaborations in Japan and Germany. His work actively contributes to UN Sustainable Development Goals for Industry/Innovation and Quality Education.

• First Year Student Learning
• Biomedical Education
• Physiology Education
• +۵ مورد دیگر

Professor Kathy Tangalakis is a distinguished academic at Victoria University's First Year College, where she serves as Deputy Head of Scholarship & Professional Learning. With a career focused on enhancing first-year student learning experiences, particularly in biomedical and health-related courses, she has made significant contributions to educational innovation through Victoria University's Block Model teaching approach. Her work extends nationally through her co-chair position with the National Biomedical Assessment Collaboration, which aims to build a national Assessment Framework for biomedical and biosciences education. Dr. Tangalakis earned her BSc (Hons) in 1988 and PhD in 1992, both from the University of Melbourne. Her academic journey has led her through various leadership roles including: Course Coordinator, Bachelor of Science (Biomedical Sciences) (2008-2010) Academic Coordinator (Teaching & Learning), School of Biomedical Sciences (2009-2012) Head of Discipline (Medical Physiology), College of Health & Biomedicine (2014-2016) First Year Champion, College of Health & Biomedicine (2014-2016) Course leader, Bachelor of Biomedicine (2015-2015) Deputy Head of Scholarship & Professional Learning, First Year College (2018-present) Professor Tangalakis's research interests center on innovative approaches to first-year STEM education, particularly through the Block Model teaching system. She investigates how this innovative approach impacts student outcomes, with a special focus on diverse student cohorts in biomedical and health-related courses. Her work with the National Biomedical Assessment Collaboration has led to the development of a comprehensive Assessment Framework designed to map and improve assessment quality across Australian biomedical education programs. Additionally, she explores the core concepts of physiology and how they can be effectively taught and assessed across university curricula. Her publication record demonstrates a clear dual focus: educational innovation in higher education (particularly the Block Model) and physiology education. Recent articles show her leading large Australian teams to unpack and validate core physiology concepts while simultaneously examining how teaching innovations impact student learning outcomes. This dual expertise makes her work uniquely positioned at the intersection of content knowledge and pedagogical innovation. Professor Tangalakis has received numerous international, national, and institutional awards for her contributions to learning and teaching, though specific awards are not detailed in the available information. Her work has been widely recognized for its impact on student learning experiences and outcomes. As an academic supervisor, Professor Tangalakis has led and co-supervised research projects including 'New vaccines for Alzheimer's Disease: prevention as a cure' and 'Motivational interviewing in female breast cancer survivors.' Her collaborative approach to research is evident in her numerous team-based projects examining physiology education, assessment frameworks, and innovative teaching methods in the Block Model environment. Professor Tangalakis is actively involved in several collaborative networks, including her work with the Australian Council for Educational Research to improve assessment of core physiology concepts. Her research team focuses on understanding how educational innovations impact student learning, particularly for diverse cohorts in STEM disciplines.

Johannes Steinhausمشاهده پروفایل

استاد

• Polymer Science
• Polymer Recycling
• Polymer Aging
• +۶ مورد دیگر

Professor Johannes Steinhaus serves as both Vice-President for Research and Transfer (VP2) and Professor of Materials Science at Bonn-Rhine-Sieg University of Applied Sciences, specializing in hybrid material systems and failure analysis. He is affiliated with the Department of Natural Sciences and maintains offices in both Sankt Augustin and Rheinbach campuses. His research focuses on Microplastic analysis , Failure analysis , Simulation and durability analysis of rubber components , Real-time analysis of the curing behaviour of thermoset systems , Microscopy in the characterisation of plastics , and Thermal analysis methods (DSC, DMA, TGA, TMA and DEA) in polymer development. He is a member of the German Association of Materials Science (DGM). Prof. Steinhaus teaches courses including Additive Manufacturing , Biomedical Materials , Conventional Processing Techniques , Forensic Material Trace and Damage Analysis , Polymer Analytics , Recycling of Plastics and Maritime Waste Problems , and Thermal Analysis of Plastics . His publication record spans from 2005 to 2024, with recent work focusing on microplastic pollution quantification, thermal analysis of polymers, and dental composite curing behavior. His research projects include PAExSiDur (Polymer Ageing in Experiment and Simulation), NaWETec (Sustainability in Materials and Energy Technology), and Denthart. PAExSiDur - Polymer ageing in experiment and simulation for targeted service life extension MOTTSAL - Modeling and Optimization of Transdermal Therapeutic Systems NaWETec - Sustainability in Materials and Energy Technology Denthart - Investigation of curing processes of light-curing dental filling composites Prof. Steinhaus has supervised numerous Bachelor's and Master's theses, both internally and in collaboration with industry partners. His students have worked on topics ranging from microplastic analysis to polymer recycling and dental material characterization. He also organizes professional seminars, including a biennial seminar on damage analysis and component testing of plastics in collaboration with the German Society for Materials Science.